Phát hiện mới giúp điều trị hiệu quả hơn bệnh ung thư phổi
Theo các nhà nghiên cứu Mỹ, họ đã phát hiện một protein được gọi là EMP-1 có trong các khối u ở bệnh nhân ung thư phổi chính là nguyên nhân dẫn đến kháng thuốc Iressa (gefitinib), giúp cho việc điều trị căn bệnh này hiệu quả hơn.
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